HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy.

Abstract
Transforming growth factor-β (TGF-β) is key in the pathogenesis of diabetic nephropathy. Thrombospondin 1 (TSP1) expression is increased in diabetes, and TSP1 regulates latent TGF-β activation in vitro and in diabetic animal models. Herein, we investigate the effect of blockade of TSP1-dependent TGF-β activation on progression of renal disease in a mouse model of type 1 diabetes (C57BL/6J-Ins2(Akita)) as a targeted treatment for diabetic nephropathy. Akita and control C57BL/6 mice who underwent uninephrectomy received 15 weeks of thrice-weekly i.p. treatment with 3 or 30 mg/kg LSKL peptide, control SLLK peptide, or saline. The effects of systemic LSKL peptide on dermal wound healing was assessed in type 2 diabetic mice (db/db). Proteinuria (urinary albumin level and albumin/creatinine ratio) was significantly improved in Akita mice treated with 30 mg/kg LSKL peptide. LSKL treatment reduced urinary TGF-β activity and renal phospho-Smad2/3 levels and improved markers of tubulointerstitial injury (fibronectin) and podocytes (nephrin). However, LSKL did not alter glomerulosclerosis or glomerular structure. LSKL did not increase tumor incidence or inflammation or impair diabetic wound healing. These data suggest that selective targeting of excessive TGF-β activity through blockade of TSP1-dependent TGF-β activation represents a therapeutic strategy for treating diabetic nephropathy that preserves the homeostatic functions of TGF-β.
AuthorsAiling Lu, Mi Miao, Trenton R Schoeb, Anupam Agarwal, Joanne E Murphy-Ullrich
JournalThe American journal of pathology (Am J Pathol) Vol. 178 Issue 6 Pg. 2573-86 (Jun 2011) ISSN: 1525-2191 [Electronic] United States
PMID21641382 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Fibronectins
  • Leu-Ser-Lys-Leu peptide
  • Peptides
  • Smad2 Protein
  • Smad2 protein, mouse
  • Thrombospondin 1
  • Transforming Growth Factor beta
  • Creatinine
Topics
  • Albuminuria (complications, pathology, urine)
  • Amino Acid Sequence
  • Animals
  • Creatinine (urine)
  • Dermis (drug effects, pathology)
  • Diabetic Nephropathies (complications, drug therapy, pathology, urine)
  • Disease Models, Animal
  • Fibronectins (metabolism)
  • Inflammation (complications, pathology)
  • Injections, Intraperitoneal
  • Kidney (drug effects, metabolism, pathology)
  • Mice
  • Mice, Inbred C57BL
  • Molecular Sequence Data
  • Peptides (administration & dosage, chemistry, pharmacology, therapeutic use)
  • Phosphorylation (drug effects)
  • Proteinuria (complications, prevention & control, urine)
  • Signal Transduction (drug effects)
  • Smad2 Protein (metabolism)
  • Thrombospondin 1 (metabolism)
  • Transforming Growth Factor beta (antagonists & inhibitors, urine)
  • Wound Healing (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: